Interestingly, we found that co-treatment with HE led to a marked reduction in the endogenous release of the pro-fibrotic cytokine TGF-β, a key reporter of treatment efficacy, quantified by ELISA. Here, TGFB1 is linked to hereditary elliptocytosis.